{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T10:55:46Z","timestamp":1772103346126,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,10,1]],"date-time":"2004-10-01T00:00:00Z","timestamp":1096588800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2004,10]]},"DOI":"10.1136\/ard.2004.023937","type":"journal-article","created":{"date-parts":[[2004,9,10]],"date-time":"2004-09-10T23:58:49Z","timestamp":1094860729000},"page":"1183-1185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Urinary bladder cancer in Wegener's granulomatosis: is it more than cyclophosphamide?"],"prefix":"10.1016","volume":"63","author":[{"given":"B","family":"Hellmich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Kausch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Doehn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Jocham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Holl-Ulrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W L","family":"Gross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2004.023937_bib1","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1136\/ard.2003.019125","article-title":"Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide","volume":"63","author":"Knight","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2004.023937_bib2","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/1529-0131(199904)42:4<751::AID-ANR19>3.0.CO;2-D","article-title":"Wegener's granulomatosis associated with renal cell carcinoma","volume":"42","author":"Tatsis","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.023937_bib3","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/archinte.1994.00420030148015","article-title":"Clinical manifestations of vasculitis in patients with solid tumors","volume":"154","author":"Kurzrock","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1136\/ard.2004.023937_bib4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ijc.10444","article-title":"Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis","volume":"100","author":"Knight","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1136\/ard.2004.023937_bib5","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1084\/jem.171.1.357","article-title":"Anti-neutrophil cytoplasmic antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme","volume":"171","author":"L\u00fcdemann","year":"1990","journal-title":"J Exp Med"},{"key":"10.1136\/ard.2004.023937_bib6","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1365-2249.1995.tb06642.x","article-title":"Endothelial cells and renal epithelial cells do not express the Wegener's autoantigen, proteinase 3","volume":"102","author":"King","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"10.1136\/ard.2004.023937_bib7","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1046\/j.1523-1755.2000.00100.x","article-title":"Proteinase-3 mRNA expressed by glomerular epithelial cells correlates with crescent formation in Wegener's granulomatosis","volume":"57","author":"Schwarting","year":"2000","journal-title":"Kidney Int"},{"key":"10.1136\/ard.2004.023937_bib8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/ar410","article-title":"Proteinase-3 as the major autoantigen of c-ANCA is strongly expressed in lung tissue of patients with Wegener's granulomatosis","volume":"4","author":"Brockmann","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1136\/ard.2004.023937_bib9","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.4049\/jimmunol.168.6.3057","article-title":"Interaction of antibodies to proteinase 3 (classic anti-neutrophil cytoplasmic antibody) with human renal tubular epithelial cells: impact on signaling events and inflammatory mediator generation","volume":"168","author":"Hattar","year":"2002","journal-title":"J Immunol"},{"key":"10.1136\/ard.2004.023937_bib10","first-page":"831","article-title":"Proteinase 3\/myeloblastin as a growth factor in human kidney cells","volume":"16","author":"Relle","year":"2003","journal-title":"J Nephrol"},{"key":"10.1136\/ard.2004.023937_bib11","doi-asserted-by":"crossref","first-page":"47338","DOI":"10.1074\/jbc.M202789200","article-title":"Cleavage of p21waf1 by proteinase-3, a myeloid-specific serine protease, potentiates cell proliferation","volume":"277","author":"Witko-Sarsat","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1136\/ard.2004.023937_bib12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1046\/j.1365-2184.2000.00188.x","article-title":"MCF-7 mammary tumour cells express the myeloid cell differentiation controlling factor, serine protease 3\/myeloblastin","volume":"33","author":"Horman","year":"2000","journal-title":"Cell Prolif"},{"key":"10.1136\/ard.2004.023937_bib13","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.5858\/2004-128-e8-COTUBF","article-title":"Carcinosarcoma of the urinary bladder following cyclophosphamide therapy: evidence for monoclonal origin and chromosome 9p allelic loss","volume":"128","author":"Mukhopadhyay","year":"2004","journal-title":"Arch Pathol Lab Med"},{"key":"10.1136\/ard.2004.023937_bib14","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","article-title":"Wegener's granulomatosis: an analysis of 158 patients","volume":"116","author":"Hoffman","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2004.023937_bib15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-124-5-199603010-00003","article-title":"Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis","volume":"124","author":"Talar-Williams","year":"1996","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard.2004.023937_bib16","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J","article-title":"An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients","volume":"43","author":"Reinhold-Keller","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.023937_bib17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0022-5347(17)56306-5","article-title":"The incidence of bladder cancer after cyclophosphamide therapy","volume":"122","author":"Fairchild","year":"1979","journal-title":"J Urol"},{"key":"10.1136\/ard.2004.023937_bib18","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1464-410X.1975.tb03998.x","article-title":"Carcinoma of the bladder complicating cyclophosphamide therapy","volume":"47","author":"Ansell","year":"1975","journal-title":"Br J Urol"},{"key":"10.1136\/ard.2004.023937_bib19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/1097-0142(19880201)61:3<451::AID-CNCR2820610308>3.0.CO;2-G","article-title":"Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients","volume":"61","author":"Stillwell","year":"1988","journal-title":"Cancer"},{"key":"10.1136\/ard.2004.023937_bib20","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/art.1780310402","article-title":"Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis","volume":"31","author":"Stillwell","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.023937_bib21","first-page":"9","article-title":"Clinical pharmacology and evaluation of Cytoxan (cyclophosphamide)","volume":"3","author":"Coggins","year":"1959","journal-title":"Cancer Chemother Rep"},{"key":"10.1136\/ard.2004.023937_bib22","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/0006-2952(79)90222-3","article-title":"Cyclophosphamide cystitis: identification of acrolein as the causative agent","volume":"28","author":"Cox","year":"1979","journal-title":"Biochem Pharmacol"},{"key":"10.1136\/ard.2004.023937_bib23","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/bjc.1984.252","article-title":"Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study","volume":"50","author":"Hows","year":"1984","journal-title":"Br J Cancer"},{"key":"10.1136\/ard.2004.023937_bib24","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1002\/1529-0131(200012)43:12<2853::AID-ANR30>3.0.CO;2-G","article-title":"Cystitis, bladder cancer, and myelodysplasia in patients with Wegener's granulomatosis: comment on the article by Reinhold-Keller et al [letter].","volume":"43","author":"Sneller","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.023937_bib25","first-page":"2854","article-title":"Reply to: Cystitis, bladder cancer, and myelodysplasia in patients with Wegener's granulomatosis [letter]","volume":"43","author":"Reinhold","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2004.023937_bib26","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/BF00180290","article-title":"Mesna side effects which imitate vasculitis","volume":"70","author":"Reinhold-Keller","year":"1992","journal-title":"Clin Investig"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672440109X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349672440109X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2004.023937","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T11:29:02Z","timestamp":1737545342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000349672440109X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2004,10]]}},"alternative-id":["S000349672440109X"],"URL":"https:\/\/doi.org\/10.1136\/ard.2004.023937","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2004,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urinary bladder cancer in Wegener's granulomatosis: is it more than cyclophosphamide?","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2004.023937","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Copyright 2004 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}